ClinicalTrials.gg
CompletedNCT05043584Updated Jan 3, 2024

Near-infrared Autofluorescence (NIRAF)-Guided Total Thyroidectomy: Impact in Low-volume, Non-parathyroid Institutions

An interventional study of Fluobeam LX, Fluoptics, Grenoble, France in Autofluorescence, Thyroidectomy and Hypoparathyroidism, sponsored by Regional Hospital West Jutland. Completed at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-03.

Sponsored by Regional Hospital West Jutland · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Hypoparathyroidism with a site in Denmark — 3 open to participants now, 6 under way, 2 of them phase 3. Hypoparathyroidism · Denmark.

Enrollment
8th of 15
78 · median 78
Started
2021
with 2 others
No phase
5 of 21
2 open now
Registered
13th of 21
by date
Lead sponsor
1 of 21
Regional Hospital West Jutland

Among the 21 studies in Hypoparathyroidism with a site in Denmark, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2021, is one of 5 with no phase, and was the 13th registered.

Hypoparathyroidism

128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.

Browse Hypoparathyroidism studies →

Open to participants now

3 of the 21 studies in Hypoparathyroidism with a site in Denmark are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 26 Hypoparathyroidism studies recruiting now, 19 (73%) set no upper age limit and 5 (19%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hypoparathyroidism with a site in Denmark, or all of them as a file.
02

Study summary

Hypoparathyroidism is the most frequent complication in total thyroidectomy. The use of near-infrared autofluorescence (NIRAF) intraoperatively, seems to reduce the rate of transient hypoparathyroidism. Unfortunately, no effect on permanent hypoparathyroidism has been shown.

In order to cover every aspect of the impact of NIRAF in thyroid surgery, an evaluation in low-volume, non-parathyroid institutions is needed. This is the overall aim of our current studies. The objective of this specific study is to evaluate the impact of NIRAF on immediate, transient and permanent hypoparathyroidism following total thyroidectomy in low-volume, non-parathyroid institutions.

Read the detailed description

Patients referred for total thyroidectomy will undergo NIRAF-assisted surgery (Fluobeam LX) at two low-volume ENT-departments with no experience in parathyroid surgery.

PTH and ionized calcium will be assessed preoperatively, on postoperative day 1 (POD1) and minimum two months following surgery. Patients who still fulfill the criteria for hypoparathyroidism at that point will be followed until one year following surgery. The rates of immediate, transient and permanent hypoparathyroidism will be assessed and compared to a historic cohort.

03

Conditions studied

  • Autofluorescence
  • Thyroidectomy
  • Hypoparathyroidism
  • Hypocalcemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients referred for total thyroidectomy
  • Age > 18
  • Able to understand patient information
  • Able to give

Exclusion criteria

Exclusion Criteria:

  • Previous thyroid surgery
  • Need for accelerated surgery
  • Insufficient biochemical profile
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    (A): NIRAF-assisted surgery

    Patients undergoing NIRAF-assisted total thyroidectomy

    Device: Fluobeam LX, Fluoptics, Grenoble, France

Interventions

  • DeviceFluobeam LX, Fluoptics, Grenoble, France

    See arm description

06

What researchers measure

Primary outcomes

  1. Rate of hypoparathyroidism

    Time frame: Will be assessed on postoperative day one, minimum two months and one year following surgery.

Secondary outcomes

  1. Parathyroid gland identification rate

    Time frame: Will be assessed at the time of surgery

  2. Parathyroid autotransplantation rate

    Time frame: Will be assessed at the time of surgery

  3. Rate of inadvertently excised parathyroid glands

    Time frame: Will be assessed 1 month following surgery

07

Study locations

2 sites
  • Department of Otorhinolaryngology, Hospital South West Jutland
    Esbjerg, 6700, Denmark
  • Department of Otorhinolaryngology, Regional Hospital West Jutland
    Holstebro, 7500, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Dec 2023, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2021
First posted
Sep 14, 2021
StartActual
Sep 15, 2021
Primary completionActual
Dec 1, 2023
CompletionActual
Dec 1, 2023
Last update
Jan 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05043584
Lead sponsor
Regional Hospital West Jutland
Collaborators
Esbjerg Hospital - University Hospital of Southern Denmark
Responsible party
Ali Abood (Principal Investigator, Regional Hospital West Jutland) — Principal investigator
First posted
Sep 14, 2021
Start date
Sep 15, 2021
Primary completion
Dec 1, 2023
Completion
Dec 1, 2023
Last update
Jan 3, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion